Prophylactic Low Molecular Weight Heparin Improving Perinatal Outcome in Non-thrombophilic Placental-Mediated Complications

Singh, Shweta; Sinha, Renuka; Kaushik, Mayank

doi:10.1007/s13224-015-0728-3

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results were consistent with previous research results. Low molecular heparin can positively act on preeclampsia [ 18 , 19 ]. The p38MAPK signaling pathway has been reported to be related to the growth and migration of trophoblasts.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Low Molecular Heparin on Preeclampsia by Inhibiting Apoptosis of Trophoblasts via the p38MAPK Signaling Pathway

Quan

Zuo

2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. To explore the efficacy of low molecular heparin on preeclampsia by inhibiting apoptosis of trophoblasts via the p38MAPK signaling pathway. Methods. A preeclampsia rat model was established, and the effects of low molecular heparin on preeclampsia via the p38MAPK signaling pathway were analyzed based on intervention of the rats with different combinations of low molecular heparin and p38MAPK signaling pathway activator. Furthermore, a hypoxia/reoxygenation model of trophoblasts in vitro was established to explore the effects of low molecular heparin on trophoblasts via the p38MAPK signaling pathway. Results. After treatment with low molecular heparin, pregnant rats in the heparin group showed significantly decreased blood pressure, 24 h proteinuria, and p38MAPK protein levels in placenta tissues and decreased apoptosis rate of placenta tissue cells (all P < 0.05 ) and showed more fetal rats and lowered weight of them (both P < 0.05 ) but showed no significant change in the weight of placenta (all P > 0.05 ). Pregnant rats treated with low molecular heparin and p38MAPK activator showed significantly higher blood pressure, 24 h proteinuria, and p38MAPK protein levels in placenta tissues and apoptosis rate of placenta tissue cells than those of pregnant rats in the heparin group (all P < 0.05 ) and also showed less fetal rats and lighter fetal rats than those in the heparin group (both P < 0.05 ) but showed no difference with them in the weight of placenta ( P > 0.05 ). Further analysis revealed that low molecular heparin could protect the survival and migration of trophoblasts under hypoxia/reoxygenation conditions and reduce apoptosis of them (all P < 0.05 ). Conclusion. Low molecular heparin can alleviate preeclampsia by inhibiting the p38MAPK signaling pathway and can inhibit apoptosis of trophoblasts and promote proliferation and migration of them.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Low Molecular Heparin on Preeclampsia by Inhibiting Apoptosis of Trophoblasts via the p38MAPK Signaling Pathway

Quan

Zuo

2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…However, it should be used in women at high risk of maternal venous‐thromboembolism. Some smaller studies show a potential benefit; one Indian study 72 showed that prophylactic LMWH commenced before 15 weeks of gestation substantially reduced admissions to the neonatal intensive care unit (NICU) by 80%. However, the EPPI 73 and TIPPS 74 studies, which were both large, multicentre, randomised controlled trials, failed to demonstrate benefit in fetal outcomes.…”

Section: Specific Pharmacological Treatmentsmentioning

confidence: 99%

Care in pregnancies subsequent to stillbirth or perinatal death

Graham

Stephens

Heazell

2020

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

show abstract

“…Stricter stratification of patients into study groups, based not only on the history of pregnancy complications, but also on its association with genetic thrombophilia, showed more interesting results [35,61]. Thus, in particular, in the study of de Vries et al [35], including 139 women with hereditary thrombophilia, of which 82 (59.0% of 139) had FVL (1961) GA mutation, sodium dalteparin (daily at a dose of 5000 IU) in combination with acetylsalicylic acid (daily at a dose of 75-100 mg) led to Absolute Risk Reduction (ARR) of early-onset preeclampsia (up to 34 weeks) by 8.7% [95% CI (1.9-15.5) p =0.012].…”

Section: Partmentioning

confidence: 99%

Effects of Low-Molecular Heparin on Pregnant Women with Factor V Mutation (GA Genotype)

Моmot¹

2018

HBTD

View full text Add to dashboard Cite

To study the clinical laboratory results of heparin prophylaxis in women with FVL (1691) GA mutation with severe APC resistance. Material and methods: A single-center randomized controlled study of 141 pregnant women with FVL mutation (GA genotype) with APC resistance (normalized ratio of 0.49 or less) at 7-8 weeks of gestation has been conducted. The study group consisted of 70 patients who underwent courses of heparin prophylaxis during 14 days from 7-8 weeks of gestation. 71 pregnant women who received no antenatal LMWH prophylaxis were in the control group. Results: Prophylactic doses of LMWH decreased thrombin generation from 22 weeks of gestation: Peak thrombin by 9-11% (p <0.05) and ETP by 4-9% (p <0.05), also there was a decrease in APC resistance from 12 weeks by 9-14% (p <0.05) compared to pregnant women receiving standard prophylactic measures. Heparin prophylaxis in women with FVL (1961) GA mutation from 7-8 weeks of gestation reduced the absolute risk (ARR, Absolute Risk Reduction) of placenta-mediated pregnancy complications: PE by 29.5%

show abstract

Prophylactic Low Molecular Weight Heparin Improving Perinatal Outcome in Non-thrombophilic Placental-Mediated Complications

Cited by 3 publications

References 23 publications

Efficacy of Low Molecular Heparin on Preeclampsia by Inhibiting Apoptosis of Trophoblasts via the p38MAPK Signaling Pathway

Efficacy of Low Molecular Heparin on Preeclampsia by Inhibiting Apoptosis of Trophoblasts via the p38MAPK Signaling Pathway

Care in pregnancies subsequent to stillbirth or perinatal death

Effects of Low-Molecular Heparin on Pregnant Women with Factor V Mutation (GA Genotype)

Contact Info

Product

Resources

About